Mirabegron
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overactive Bladder
Conditions
Overactive Bladder, Cardiovascular Disease
Trial Timeline
Dec 1, 2012 → Mar 1, 2015
NCT ID
NCT02570035About Mirabegron
Mirabegron is a pre-clinical stage product being developed by Astellas Pharma for Overactive Bladder. The current trial status is completed. This product is registered under clinical trial identifier NCT02570035. Target conditions include Overactive Bladder, Cardiovascular Disease.
What happened to similar drugs?
10 of 20 similar drugs in Overactive Bladder were approved
Approved (10) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05621616 | Phase 3 | Active |
| NCT04562090 | Approved | Completed |
| NCT04501640 | Approved | Completed |
| NCT02981459 | Approved | Withdrawn |
| NCT02916693 | Phase 1/2 | Completed |
| NCT02751931 | Phase 3 | Completed |
| NCT02526979 | Phase 1 | Completed |
| NCT02495389 | Approved | Completed |
| NCT02211846 | Phase 1 | Completed |
| NCT01898624 | Pre-clinical | Completed |
| NCT02570035 | Pre-clinical | Completed |
| NCT00939757 | Phase 1 | Completed |
| NCT01285596 | Phase 1 | Completed |
| NCT01579461 | Phase 1 | Completed |
Competing Products
20 competing products in Overactive Bladder